Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

SNX33 Inhibitors

SNX33, or Sorting Nexin 33, is part of the sorting nexin family-a diverse group of proteins characterized by the presence of a particular phospholipid-binding motif known as the PX (Phox homology) domain. Sorting nexins are involved in various aspects of intracellular trafficking, including endocytosis, protein sorting, and protein degradation. These proteins play crucial roles in directing cellular cargo, like proteins and lipids, to their proper destinations within the cell. The PX domain allows sorting nexins, including SNX33, to interact with specific phospholipids present in cellular membranes, thereby determining the subcellular localization and function of these proteins. SNX33 inhibitors would be molecules designed to modulate the function, expression, or stability of SNX33. Given the protein's role in intracellular trafficking, inhibiting its function could potentially disrupt the proper sorting and transport of cellular cargo, leading to alterations in cell signaling, protein degradation, or other processes dependent on accurate protein localization. Potential inhibitors might encompass small molecules that either bind directly to SNX33 or to its PX domain, preventing its interaction with specific phospholipids and other protein partners. Another approach could involve molecules that alter post-translational modifications of SNX33, potentially affecting its localization or interactions with other cellular components. Additionally, molecular strategies such as RNA interference could be employed to reduce SNX33 expression at the transcriptional or translational level. Delving into the effects of SNX33 inhibition can provide insights into its specific roles in intracellular trafficking and the broader implications of modulating this vital cellular process. Such knowledge would contribute to a more profound understanding of cell biology and the intricate mechanisms governing intracellular transport and signaling.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Dynamin Inhibitor I, Dynasore

304448-55-3sc-202592
10 mg
$89.00
44
(2)

Dynasore is a non-competitive inhibitor of dynamin, essential for endocytosis. Inhibiting endocytosis might affect SNX33 expression due to disrupted protein trafficking.

Chlorpromazine

50-53-3sc-357313
sc-357313A
5 g
25 g
$61.00
$110.00
21
(1)

Chlorpromazine inhibits clathrin-mediated endocytosis. As endocytosis is integral to SNX33's role, its inhibition might impact SNX33 expression.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin inhibits PI3K, a kinase involved in vesicle trafficking. This can influence endosomal processes and potentially SNX33 expression.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

Bafilomycin A1 inhibits the vacuolar ATPase (V-ATPase), affecting vesicle acidification. This might disrupt SNX33-related processes and affect its expression.

Monensin A

17090-79-8sc-362032
sc-362032A
5 mg
25 mg
$155.00
$525.00
(1)

Monensin is an ionophore that disrupts endosomal-lysosomal trafficking. This might influence SNX33 expression due to disrupted protein sorting.

U 18666A

3039-71-2sc-203306
sc-203306A
10 mg
50 mg
$143.00
$510.00
2
(1)

U18666A can induce a phenotype resembling Niemann-Pick disease, affecting lysosomal function and potentially influencing SNX33 expression.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

As a PI3K inhibitor, LY294002 can affect vesicle trafficking pathways, which might indirectly impact SNX33 expression.

Autophagy Inhibitor, 3-MA

5142-23-4sc-205596
sc-205596A
50 mg
500 mg
$65.00
$261.00
113
(3)

3-MA inhibits PI3K, known to affect autophagy. Given the relationship between endosomes and autophagosomes, SNX33 expression might be influenced.

5-(N-Ethyl-N-isopropyl)-Amiloride

1154-25-2sc-202458
5 mg
$104.00
20
(1)

EIPA inhibits macropinocytosis, another form of endocytosis. This might indirectly influence SNX33 expression.

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$45.00
$164.00
$200.00
$402.00
$575.00
$981.00
$2031.00
46
(1)

Genistein inhibits tyrosine kinases, which can be involved in various cellular signaling pathways, including vesicle trafficking that might impact SNX33.